February 08, 2024

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai-400051

Symbol: **ORCHPHARMA**

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai-400001

Scrip Code: **524372**

Subject: **Investors Presentation for the Quarter 3rd ended on December 31, 2023 of Financial Year 2023-24 – Orchid Pharma Limited ("the Company")**

Dear Sir/Madam,

In continuation to our earlier intimation letter dated February 05, 2024 regarding the Analysts/ Investors Earning Call scheduled to be held on February 09, 2024 at 05:00 P.M. (IST) and in accordance to the requirement of Regulation 30 of SEBI (Listing Obligation and Disclosures Requirement) Regulations, 2015, please find enclosed the Investor Presentation on the financial highlights of the Company w.r.t the quarter ended on December 31, 2023.

The Investor Presentation is also made available on the website of the Company at www.orchidpharma.com

You are requested to take the above on your record.

Thanking You,
For **Orchid Pharma Limited**

KAPIL DAYYA Digitally signed by KAPIL DAYYA Date: 2024.02.08 23:16:47 +05'30'

Kapil Dayya
Company Secretary & Compliance Officer

Encl.: as above

Orchid Pharma Limited

Financials Oct-Dec 2023

Financial Highlights Q3 FY24

OrchidPharma — A Dhanuka Group Company —

Top line	38%
EBIDTA	92%
PBT	355%
PAT	355%

* Compared with 9M FY23

Financial Highlights

OrchidPharma
— A Dhanuka Group Company —

(Rs/Crore)	Q3-2023	Q3-2022	Change %	9M-31st Dec'23	9M-31st Dec'22	Change %
Sales	220.6	159.8	+38%	602.3	456.0	+32%
Other Income	7.4	8.9		17.5	17.7	
COGS	121.9	95.6		356.4	265.7	
Employee Exp	18.7	16.7		52.1	49.0	
Other Exp	44.1	33.8		112.1	97.4	
EBITDA	43.3	22.6	+92%	99.3	61.6	+61%
% to Sales	20%	14%		16%	14%	
Interest	3.5	7.7	-55%	12.9	24.7	-48%
Depreciation	9.3	8.2	+13%	24.8	47.6	-48%
PBT	30.5	6.7		61.6	-10.7	
PAT	30.5	6.7		61.6	-10.7	

Financial Highlights

OrchidPharma
— A Dhanuka Group Company —

Growth Criteria	Q3 23-24	Q2 23-24	Q1 23-24	9ME 23-24
Turnover	38%	20%	40%	32%
EBIDTA	92%	34%	57%	61%
PBT	355%	712%	177%	676%
PAT	355%	712%	177%	676%

* YoY Comparison with FY23

Turnover (In Cr.)



P&L Analysis – Exp. % to sales 9M



EBIDTA & PAT as % to sales 9ME Dec



Thanks